Weekly Digest – September 2025 Weekly Digest – September 2025 15 September 2025: Spera Pharma and Mycenax forge strategic alliance to streamline ADC drug substance and drug product manufacturing services Spera Pharma and Mycenax Biotech have formed a strategic alliance […]
Weekly Digest – September 2025 Weekly Digest – September 2025 15 September 2025: Biocytogen announces ADC innovator Tubulis has signed global exclusive license agreement for single antibody Biocytogen announced that Tubulis has exercised an exclusive license for the global development […]
Weekly Digest – September 2025 Weekly Digest – September 2025 11 September 2025: ENHERTU Type II variation application validated in the EU for previously treated patients with HER2 positive metastatic solid tumors The EMA has validated a Type II Variation […]
Weekly Digest – September 2025 Weekly Digest – September 2025 08 September 2025: The clinical trial approval for SIM0609 (CDH17 Antibody-Drug Conjugate) issued by the National Medical Products Administration Simcere Pharmaceutical Group announced that its CDH17-targeting ADC SIM0609 received clinical […]
Weekly Digest – September 2025 Weekly Digest – September 2025 11 September 2025: Chime Biologics and Arbele announce strategic collaboration at BIOHK 2025 signing ceremony Chime Biologics and Arbele signed a strategic collaboration agreement at BIOHK 2025 to advance innovative […]
Weekly Digest – September 2025 Weekly Digest – September 2025 09 September 2025: LigaChem Biosciences enters license agreement with GO Therapeutics LigaChem Biosciences signed a licensing agreement with U.S. based GO Therapeutics to develop and commercialize ADCs using GO’s antibody […]
Weekly Digest – September 2025 Weekly Digest – September 2025 09 September 2025: Daiichi Sankyo breaks ground on $151M cancer drug plant in Shanghai Daiichi Sankyo has begun building a 1.1 billion yuan ($151 million) facility in Shanghai to manufacture […]
Weekly Digest – September 2025 Weekly Digest – September 2025 09 September 2025: Ridge Biotechnologies emerges from stealth with $25 million in seed financing for AI-Enabled precision enzyme and targeted drug design Ridge Biotechnologies emerged from stealth with $25 million in […]
Weekly Digest – September 2025 Weekly Digest – September 2025 01 September 2025: Zai Lab announces approval of TIVDAK for patients with recurrent or metastatic cervical cancer in Hong Kong Zai Lab announced that the Hong Kong Department of Health […]
Weekly Digest – September 2025 Weekly Digest – September 2025 02 September 2025: Health Canada approves ELAHERE for certain types of platinum resistant ovarian cancers Health Canada has approved ELAHERE (mirvetuximab soravtansine), an antibody-drug conjugate, for adult patients with folate […]
